Objectives:

1. Continued reduction in CVD events with LDL-C reductions to very low levels <25 mg/dL.

2. Lack of adverse events with LDL-C reduced to <25 mg/dL with PCSK9 monoclonal antibodies.

3. Unreliability of calculated LDL-C by Friedewald formula when LDL-C decreases below 50 mg/dL.

 

Session date: 
Friday, January 12, 2018 - 12:00pm to 1:00pm
Speaker Name: 
Evan A Stein MD PhD FRCP(C) FCAP
Location: 
UCMC
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.